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Abstract
Resting memory CD4
+ T-cells harboring latent HIV proviruses represent a critical barrier to viral eradication. Histone
deacetylase inhibitors (HDACis), such as suberanilohydroxamic acid (SAHA), romidepsin, and panobinostat have been
shown to induce HIV expression in these resting cells. Recently, it has been demonstrated that the low levels of viral gene
expression induced by a candidate HDACi may be insufficient to cause the death of infected cells by viral cytopathic effects,
necessitating their elimination by immune effectors, such as cytotoxic T-lymphocytes (CTL). Here, we study the impact of
three HDACis in clinical development on T-cell effector functions. We report two modes of HDACi-induced functional
impairment: i) the rapid suppression of cytokine production from viable T-cells induced by all three HDACis ii) the selective
death of activated T-cells occurring at later time-points following transient exposures to romidepsin or, to a lesser extent,
panobinostat. As a net result of these factors, HDACis impaired CTL-mediated IFN-c production, as well as the elimination of
HIV-infected or peptide-pulsed target cells, both in liquid culture and in collagen matrices. Romidepsin exerted greater
inhibition of antiviral function than SAHA or panobinostat over the dose ranges tested. These data suggest that treatment
with HDACis to mobilize the latent reservoir could have unintended negative impacts on the effector functions of CTL. This
could influence the effectiveness of HDACi-based eradication strategies, by impairing elimination of infected cells, and is a
critical consideration for trials where therapeutic interruptions are being contemplated, given the importance of CTL in
containing rebound viremia.
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Introduction
Antiretroviral therapy (ART) is capable of durably suppressing
viremia in HIV-infected subjects, but is unable to cure infection.
The financial and psychological burden of lifelong therapy, as well
as a growing appreciation for co-morbidities that occur in HIV-
infected individuals on long-term therapy, such as cardiovascular
disease and neurocognitive disorders, have led to the prioritization
of HIV cure research [1,2]. The best understood, and perhaps
most obstinate, barrier to eradicating infection is the existence of a
pool of infected resting memory CD4
+ T-cells [3–5]. By virtue of
their quiescent state, these cells are not thought to express HIV
antigens, rendering them invisible to the immune system. These
cells are very long-lived, with an estimated half-life of 44 months,
suggesting that 60 years of uninterrupted ART would be required
for full decay of the reservoir [6]. As the reservoir almost certainly
replenishes itself through ongoing rounds of re-infection and
homeostatic proliferation, it is unlikely that current ART regimens
could cure an individual within a lifetime [7,8].
Such theoretical and experimental analyses have led to the
consensus that the eradication of HIV from an infected individual
will require a means for actively depleting the resting CD4
+ T-cell
reservoir, most likely to be achieved by inducing viral expression
that could trigger immune-mediated clearance of infected cells.
While a variety of compounds have been shown to reactivate virus
from CD4
+ T-cells, a class of drugs known as histone deacetylase
inhibitors (HDACis) has emerged as the front-runner and a
number of these, including vorinostat (suberoylanilide hydroxamic
acid or SAHA), romidepsin, and panobinostat, have entered into
HIV clinical trials aimed at testing their abilities to reduce or
eradicate viral reservoirs in the context of ART [9–11] (reviewed
in [12]).
It was initially thought that the reactivation of latent HIV by
HDACis would be sufficient to eliminate infected cells through
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treatment of patient PBMCs with 500 nM SAHA failed to lead
to a reduction in inducible viral reservoirs, suggests that this may
not be the case, and that immune effectors, such as HIV-specific
cytotoxic T-lymphocytes (CTL), natural killer (NK) cells, or
immunotoxins will likely be needed to recognize and eliminate
these exposed target cells in so called ‘flush-and-kill’ strategies [13].
Notably, in this same study, CD8
+ T-cells freshly isolated from
ART-treated HIV-infected patients could eliminate infected cells
in a primary cell model of latency only if pre-stimulated with
peptides and IL-2 ex vivo [13], highlighting that, in the case of
CTL-based flush-and-kill strategies, the functional state of virus-
specific CD8
+ T-cells will be important for reservoir elimination.
In evaluating strategies predicated upon coordinating CTL with
latency-reversing drugs it is critical to consider potential side effects
of these drugs on CTL function. This is particularly true in the
case of HDACis, which are known to exert potent and diverse
effects on both the innate and adaptive immune system (reviewed
in [14] and [15]). A number of HDACis, including SAHA, have
been shown to suppress the production of inflammatory cytokines
by both T-cells and innate immune cells, in vitro and in vivo [16–
21]. SAHA, romidepsin, and other HDACis have also been shown
to interfere with the differentiation of monocytes into dendritic
cells (DCs), as well as to block the ability of DCs to upregulate
CD1a, CD80, CD83 and other co-stimulatory molecules, resulting
in impaired priming of T-cells [22–26]. These immunosuppressive
activities of HDACis have been associated with therapeutic
benefits in murine models of graft-versus-host disease (GVHD)
and autoimmune/inflammatory disorders such as autoimmune
lymphoproliferative syndrome, experimental autoimmune enceph-
alomyelitis (EAE, a model of multiple sclerosis), and diabetes
mellitus [27–32].
While it is tempting, based on this body of evidence, to generally
characterize HDACis as immunosuppressive agents, this would
not be an accurate assessment. The HDACi panobinostat
(LBH589), which is also in clinical trials for HIV eradication
(CLEAR trial, ClinicalTrials.gov Identifier NCT00256139), has
been reported to enhance T-cell activation in vivo, resulting in
elevated serum Th1 cytokines and accelerated progression in a
murine model of graft-versus-host disease [33]. Even within an
individual, the effects of a given HDACi have been reported to be
divergent depending upon the particular facet of the immune
response being studied. For example, in a murine model of
allogeneic bone marrow transplantation it has been shown that
SAHA decreased levels of serum cytokines and GVHD while
having no effect on donor T-cell proliferation or killing of host cells
[20]. In a second example, co-administration of the HDACi MS-
275 with a viral-vectored vaccine served to suppress the immune
response to the vector, while enhancing the response to the viral
vector insert and suppressing autoimmune pathology [34].
This diversity of effects of HDACis on immune cells is likely
rooted in two sources. First, there are 18 different HDAC enzymes
in humans, divided into four different families. Different HDACi
drugs interact with different subsets of these enzymes, depending
upon the dose being used [35]. Second, in addition to altering
histone acetylation status, and thus chromatin structure, HDACis
can interact with multiple transcription factors, including NF-kB,
AP-1, and others either by interfering with co-repressor HDAC
enzymes that are recruited to transcription factor binding sites
resulting in enhanced transcription, or by directly blocking
deacetylation of the transcription factor itself [36–40]. Foxp3, for
example, requires acetylation of lysine residues for maximal
activation. HDACis, by preventing deacetylation of Foxp3,
enhance its activity and thus boost the numbers and function of
Tregs in vivo [41]. Other nonhistone proteins that serve as direct
HDAC substrates include p53, GATA-1, STAT3, and STAT5
[42,43]. This high degree of complexity, both in terms of
immunological outcomes and underlying mechanisms, necessitates
that HDACis be studied in a context that is matched to their
intended utility. Thus, there is a need to understand the impact of
HDACis being taken forwards in flush-and-kill eradication
strategies on the abilities of HIV-specific CTL to eliminate
infected target cells.
Here, we report a series of experiments designed to assess the
effects of the HDACis currently being tested in HIV eradication
clinical trials on the in vitro function of virus-specific T-cells. We
show that, while the HDACis tested did not exhibit detectable
toxicity to ex vivo bulk CD8
+ T-cells over the doses and time-
courses tested, romidepsin and, to a lesser extent, panobinostat
exhibited delay toxicity to activated CD8
+ T-cells and to CTL
clones. Each of the HDACis tested rapidly suppressed the
production of IFN-c from PMA/ionomycin by ex vivo stimulated
CD8
+ and CD4
+ T-cells at an early time-point not associated with
losses in viability. The production of IFN-c in response to peptides
representing viral epitopes was rapidly and durably suppressed by
treatment of both CTL clones and ex vivo CD8
+ T-cells with
HDACis. Treatment with romidepsin abrogated the proliferation
of HIV-Gag- and CMV-pp65-specific CD8
+ and CD4
+ T-cells,
while panobinostat and SAHA only significantly impaired
proliferation of CMV-pp65-specific CD8
+ T-cell responses. Of
principal importance, we observed that each of the HDACis tested
exhibited significant impairment of the abilities of CTL clones to
eliminate HIV-infected target cells. These results indicate that
HDACis can exert negative effects on the CTL that may be
needed for flush-and-kill approaches to eradication.
Results
Effects of HDAC Inhibitors on T-Cell Viability over a
21 Hour Time-Course
As a prerequisite to assessing the effects of HDACis on T-cell
function, we first measured the impact of HDACi treatment on
Author Summary
The advent of antiretroviral therapy has greatly improved
the prognosis for HIV-infected individuals with access to
care. However, current therapies are unable to cure
infection, committing treated individuals to a lifetime of
medication with significant economic burden. Further-
more, it has become clear that antiretroviral therapy does
not completely restore health, leaving treated HIV-infected
individuals at increased risk of cardiovascular disease,
neurological disorders, and other health issues. Thus, there
is a need to develop therapies capable of curing HIV
infection. It is thought that, to be successful, curative
strategies will need to combine a means to flush the virus
out of the latently-infected cells in which it hides, with a
means to kill these unmasked targets. A front-running
approach proposes to use a class of drugs called histone
deacetylase inhibitors (HDACis) as flushing agents, with
cytotoxic T-lymphocytes (CTL, or killer T-cells) to purge
viral reservoirs. Here, we uncover an unexpected negative
interaction between these two agents, whereby HDACis
suppress the ability of CTL to kill HIV-infected cells. This
interaction has the potential to limit the effectiveness of
combining CTL with HDACis in flush and kill approaches to
HIV eradication, and should be considered in the prioriti-
zation and optimization of potential curative strategies.
HDACis Impair CTL Killing
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donor were treated separately with serial dilutions of romidepsin,
panobinostat or SAHA at pharmacologically relevant concentra-
tions (see Methods for justification of concentration ranges
selected). At 4 and 21 hour time-points cells were stained with
7-Aminoactinomycin D (7-AAD, stains DNA of dead cells) and
fluorochrome-conjugated annexin-V (stains phosphotidyl serine,
an early apoptosis marker) and analyzed by flow cytometry. At
4 hours of treatment we did not observe significant loss of cell
viability under any of the treatment conditions tested (Fig. 1A–C).
At 21 hours of treatment we continued to observe a lack of impact
of HDACi treatment on CD8
+ T-cell viability, but did observe a
significant induction of CD4
+ T-cell death at doses of 50 and
100 nM, reaching 21.460.9% dead cells with 100 nM romidep-
sin, (p=0.0038 compared to no treatment)) (Fig. 1A–C). Neither
SAHA nor panobinostat was associated with loss of T-cell viability
at 21 hours.
The effects of HDACis on cell viability were also assessed using
pulse-wash experimental setup with cryopreserved PBMC from
two HIV-infected ARV-treated subjects. Cells were treated with
drugs for 6 hours, washed, plated in fresh medium, and then
viability was assessed at 16, 21, and 28 hours by 7-AAD staining
and flow cytometry. Beginning at 21 hours, significant losses in
viability were only observed in CD4
+ T-cells upon treatment with
higher concentrations of romidepsin or panobinostat, and these
increased by 28 hours. A significant loss in CD8
+ T-cell viability
was only observed with 100 nM romidepsin in cells from one of
the two subjects at the 28 hour time-point (Supporting Fig. S1).
No significant losses in viability were observed in association with
treatment with up to 1,000 nM of SAHA in this experiment (data
not shown). Thus, while relatively high doses of romidepsin and
panobinostat negatively impacted the viability of CD4
+ T-cells, no
effects on bulk CD8
+ T-cell viability were observed out to
21 hours.
Romidepsin and Panobinostat Are Disproportionately
Toxic to Activated T-Cells, Including CTL Clones
We also tested the effects of HDACis on CTL clones. Following
4 hours of exposure we did not observe losses in cell viability at the
doses tested (Fig. 1D). However, 21 hours of sustained exposure
led to significant losses in CTL viability with as little as 25 nM
romidepsin, but not with panobinostat or SAHA (Fig. 1D). To
further explore this, we tested the effects of a 4 hour pulse/wash
exposure to romidepsin, panobinostat, and SAHA on the viability
of the same clone, and on an additional clone, specific for HIV-
Env-VPVWKEATTTL. We observed high levels of CTL death
with romidepsin treatment that were significant with as little as
6 nM of drug (Fig. 2A). Substantially less cell death was observed
with equivalent concentrations of panobinostat, however signifi-
cant effects were still detected at 25 and 50 nM of drug for the
Env-specific CTL clone, and at 50 nM for the Gag-specific CTL
clone. No significant losses in viability were observed with up to
1,000 nM of SAHA (data not shown). We posited that the
differential level of toxicity of romidepsin and panobinostat
towards CTL, versus ex vivo T-cells, may be attributable to the
greater activation state of the former. To test this, PBMC from an
ARV-treated HIV-infected subject were thawed and stimulated
with anti-CD3 of anti-CD28 antibodies for 48 hours. These cells
were pulsed with the indicated doses of HDACis for 4 hours, drugs
were washed out, cells were cultured for an additional 17 hours,
and viability was assessed. Parallel treatments were performed on
PBMC directly after thawing without stimulation. As in previous
experiments, we observed only low levels of cell death in HDACi-
treated unstimulated T-cells (Fig. 2B, left panel). We observed
strikingly higher levels of cell death in stimulated CD8
+ and CD4
+
T-cells (Fig. 2B, right panel). As with CTL clones, romidepsin
exhibited substantially greater toxicity to activated cells than
panobinostat, particularly at the lower concentrations. In parallel
to the viability experiments, to confirm the activity of our drugs,
we tested these same stocks of romidepsin and panobinostat for
their ability to reverse HIV latency in the ACH2 cell line model
[44], and observed very similar dose response curves (Fig. 2C).
Thus, romidepsin and panobinostat are disproportionately toxic to
activated T-cells, including those that have received short-term
(48 hour) TCR stimulation. Romidepsin was substantially more
toxic to CTL and activated T-cells than panobinostat, despite
similar potencies of latency-reversal by these two drugs as
measured against a cell line model.
HDAC Inhibitors Impair IFN-c Production from T-Cells
before Losses in Viability Occur
Next, we measured the effects of exposure to HDACis on IFN-c
production from ex vivo T-cells. PBMC from an ARV-treated
HIV-infected subject were exposed to the indicated concentrations
of HDACis for 4 hours, and then stimulated with PMA/
ionomycin for 5 hours. We observed that romidepsin, panobino-
stat, and SAHA each significantly suppressed the production of
IFN-c by both CD8
+ and CD4
+ T-cells at these pharmacologically
relevant concentrations (Fig. 3A), without any significant losses in
cell viability (Fig. 3B). Thus, while in previous experiments
treatment with romidepsin and, to a lesser extent panobinostat,
resulted in the death of activated T-cells at relatively late time-
points post-exposure, treatment with all three HDACis was also
found to suppress IFN-c production at early time-points, before
any losses in viability were detectable.
HDAC Inhibitors Exert Rapid and Durable Suppression of
IFN-c Production from HIV-Specific Antigen-Stimulated
CD8
+ T-Cells
We next measured the effect of exposure to HDACis on
cytokine production from virus-specific CD8
+ T-cells using IFN-c
ELISPOT assays. CMV-pp65- and HIV-Nef-RW8-specific CD8
+
T-cell clones isolated from two ARV-treated HIV-infected subjects
were treated with the indicated pharmacologically relevant
concentrations of romidepsin, panobinostat, or SAHA. As a point
of contrast we also included conditions where cells were pre-
treated with ALT-803, an IL-15 superagonist expected to increase
IFN-c ELISPOT responses (see Methods). Following 2 hours of
treatment with the designated concentrations of HDACis or ALT-
803, CTL clones were cultured with autologous BLCL targets in
ELISPOT plates, and stimulated for 12 hours with cognate
peptides (without washing to remove HDACis or ALT-803). For
both CTL clones, we observed that treatment with romidepsin,
panobinostat, or SAHA resulted in reduced frequencies of T-cell
responses, measured in spot-forming cells (SFCs) as compared to
untreated controls (Fig. 4A). Inhibition of cytokine production
was dose dependent, and particularly marked for romidepsin,
where IFN-c production was essentially abolished. In contrast, the
IL-15 superagonist ALT-803 enhanced frequencies of IFN-c
producing cells.
We then tested the effects of these drugs on IFN-c production
from CD8
+ T-cells directly ex vivo from ARV-treated HIV-
infected subjects. PBMC were treated with HDACis or ALT-803
for 2 hours then peptides representing optimal CD8
+ T cell
epitopes that been previously mapped in these subjects were added
(without washing to remove HDACis). We observed that, as with
CTL clones, all three of the HDACis tested suppressed
HDACis Impair CTL Killing
PLOS Pathogens | www.plospathogens.org 3 August 2014 | Volume 10 | Issue 8 | e1004287HDACis Impair CTL Killing
PLOS Pathogens | www.plospathogens.org 4 August 2014 | Volume 10 | Issue 8 | e1004287HIV-specific IFN-c production from ex vivo samples in a dose-
dependent manner (Fig. 4B). In contrast, treatment with IL-15
superagonist resulted in a significant increase in IFN-c production.
The above ELISPOT assays were based on 16 hour peptide
stimulation periods, with the final readout representing the
cumulative IFN-c production over this period. Based on the data
presented in Figs. 2 and 3 we postulated that two factors may
have contributed to this net loss in IFN-c production: i) the rapid
suppression of IFN-c production from viable cells at early time-
points post-stimulation and ii) particularly in the case of
romidepsin, the death of HDACi exposed stimulated cells at later
time-points. The involvement of both of these factors would result
in the HDACi suppressive effect being both rapid in onset and
durable, as HDACi wash-out periods would not reverse losses in
IFN-c production caused by the death of antigen-specific cells. We
tested this by probing the kinetics of this suppressive effect. To test
the contributions of the former, we performed short-term
treatments, with 2 hour exposures of ex vivo PBMC to either
romidepsin or SAHA, followed by 6 hour stimulations with the
HIV-Gag optimal epitope AW11. To test the latter, we exposed
PBMCs with romidepsin or SAHA for 2 hours, washing to remove
the drug, culturing for 24 hours in the absence of drug, and then
stimulating with peptide for 12 hours in ELISPOT assays (24 hour
washout). We observed the dose-dependent impairment of IFN-c
production in both the 6 hour stimulation and 24 hour wash-out
assays following treatment with romidepsin (Fig. 2C). With
SAHA treatment, rapid impairment was observed in 6 hour
ELISPOT assays, but this was largely normalized following a
24 hour washout period. Panobinostat was not tested in this assay.
Thus each of the HDACis studied suppress IFN-c production
from HIV-specific CD8
+ T-cells (both ex vivo and CTL clones).
This effect was rapid in onset for both romidepsin and SAHA, and
in the case of romidepsin was sustained following removal of drug
(for at least 24 hours). While we were unable to directly measure
the viability of the antigen-specific T-cells at the end of these
ELISPOT assays, our data with anti-CD3 stimulated cells
(Fig. 2B) support the idea that the inability of these T-cells to
recover over a 24 hour period may reflect the selective depletion of
these cells by the combination of antigenic stimulation and
romidepsin treatment.
HDAC Inhibitors Differentially Impair Proliferation of
Virus-Specific CD8
+ T-Cells
Next we tested the effects of HDACis on the proliferation of
CD8
+ T-cells in response to HIV-Gag and CMV-pp65 peptide
pools using a standard CFSE proliferation assay. We reasoned that
in vivo there would be a delay between the time of HDACi
administration and the expression of HIV antigens, during which
antigen-specific T-cells would be exposed to drugs. For a single
round of HDACi administration, cells that recognized induced
HIV antigens would have a chance to recover from any effects of
HDACis upon drug clearance, and potentially proliferate. To
model this scenario, PBMCs were exposed to HDACis or
ALT-803 for 4 hours prior to addition of specific peptides. Cells
were then co-cultured with HDACis and peptide for 48 hours,
washed extensively, and resuspended in fresh medium with 20 U/
ml IL-2 for an additional 5 days. We observed the proliferation of
CD8
+ T-cells in response to CMV-pp65 peptide pools (Fig. 5A),
and a lesser degree of proliferation in response to HIV-Gag
peptide pools (data not shown). Romidepsin, at the pharmacolog-
ically relevant dose of 25 nM, abrogated proliferation of CD8
+ T-
cells in response to both peptide pools (Fig. 5A, B). CD8
+ T-cells
treated with 25 nM panobinostat or 500 nM SAHA (also
pharmacologically relevant concentrations, see Methods) exhibited
significantly reduced proliferation in response to CMV-pp65 than
untreated controls (panobinostat – p=0.042, SAHA – p=0.024,
Fig. 5C and D). Statistically significant effects of panobinostat or
SAHA on the proliferation of CD8
+ T-cells in response to HIV-
Gag were not observed. However, our sensitivity to detect such an
effect may have been limited by the relatively low levels of baseline
proliferation in response to Gag. As a point of contrast, the IL-
15SA ALT-803 significantly enhanced the proliferation of CD8
+
T-cells in response to both CMV-pp65 and HIV-Gag peptide
pools.
In these experiments we also examined the effects of HDACis
on CD4
+ T-cell proliferation (Fig. 5B, C, D). As with CD8
+ T-
cells, we observed that romidepsin abrogated proliferation of
CD4
+ T-cells in response to either HIV-Gag or CMV-pp65
peptide pools. A consistent effect on CD4
+ T-cell proliferation was
not observed for either panobinostat or SAHA in response to
either HIV-Gag or CMV-pp65.
To further test the durability of the inhibition of T-cell
proliferation by romidepsin we performed a variation on the
above experiment where, after washing out drugs and peptides at
48 hours, additional peptides were added back along with the
fresh medium. We observed significant inhibition of proliferation
of CD8
+ T-cells (p=0.005), and a trend towards reduced
proliferation of CD4
+ T-cells (p=0.067) in response to HIV-
Gag peptides, despite 5 days of antigenic stimulation in the
absence of drug (Fig. 5F). As with the IFN-c ELISPOT results,
the selective depletion of antigen-specific cells by stimulation in the
presence of romidepsin may explain the lack of recovery following
a romidepsin wash-out period. Thus, HDACis differentially affect
the proliferation of T-cells in response to viral peptides, with
romidepsin abrogating proliferation of CD8
+ and CD4
+ T-cells in
response to either CMV-pp65 or HIV-Gag peptides, while
panobinostat and SAHA only exhibited significant suppression
of CMV-pp65-specific CD8
+ T-cells.
HDAC Inhibitors Impair CTL Killing of HIV-Infected CD4
+
Target Cells
Of greatest relevance to flush and kill approaches to HIV
eradication is whether HDACis impact the ability of CTL to kill
HIV-infected target cells. We tested this using several variations of
an infected-cell elimination assay. HLA-A02
+ primary CD4
+ T-
cells were infected with HIV JR-CSF and then co-cultured with
Figure 1. Effects of HDACis on the viability of PBMC CD8
+ and CD4
+ T-cells. A–C. PBMC were treated with HDACi drugs at the indicated
concentrations for either 4 or 21 hours (drugs left in) then stained with Annexin-V-Fitc (stains phosphatidyl serine on apoptotic cells), 7-AAD (stains
DNA of dead cells), CD4 pacific blue, and CD8 alexa-fluor 700 and analyzed by flow cytometry. A. Shown are representative flow cytometry data
indicating gating on dead (Annexin-V
+7-AAD
+) and dying (Annexin-v
bright7-AAD
dim/2) cells. B, C. Shown are summary data for treatments PBMC
gated on CD8
+ cells (left panel) or CD4
+ cells (right panel) with romidepsin and panobinostat (B) or with SAHA (C) at the indicated doses for the
indicated times. P values for comparisons between the multiple doses of romidepsin tested and the untreated condition were calculated by Kruskal-
Wallis test and found to be significant for ex vivo CD4
+ T-cells (p=0.0080). Post-hoc Dunn’s multiple comparison tests were performed for each of
these and the indicated p values are adjusted for multiple testing. Other drug treatment conditions and cell types were not significant by Kruskal-
Wallis tests. D. The effects of HDACi treatment on the viability of an HIV-Gag-SLYNTVATL-specific T-cell clone were determined in the same manner as
for PBMC, including use of the same statistical tests. Error bars represent SD. * p,0.05, ** p,0.01, *** p,0.001, **** p,0.0001.
doi:10.1371/journal.ppat.1004287.g001
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specificity that had been pre-treated for 2 hours with HDACi
drugs at various effector:target ratios. Following a 16 hour co-
culture in the continued presence of HDACis, we determined the
frequency of HIV-infected cells by flow cytometry and compared
this to co-cultures of untreated CTLs and infected CD4
+ cells in
the absence of HDACi. Representative control data using an
untreated HIV-Gag-SLYNTVATL-specific CTL clone are pre-
sented in Fig. 6A,B. As shown in Fig. 6C, co-cultures treated
with pharmacologically relevant doses of panobinostat and
Figure 2. Romidepsin and panobinostat are disproportionately toxic to activated CD4
+ and CD8
+ T-cells. A. HIV-Env-VL11 and HIV-Gag
SL9 specific CD8
+ CTL clones were isolated from subjects OM292 and OM9 respectively, and exposed to HDACis at the indicated concentrations for
4 hours. Cells were then washed to remove drugs and replated in fresh R10 medium supplemented with 50 U/ml IL-2 for an additional 17 hours. Cell
viability was measured by 7-AAD staining and flow cytometry. B. PBMC from subject OM292 either directly ex vivo (left panel) or following 48 hours
of stimulation with anti-CD3 and anti-CD28 (right panel) were exposed to HDACis at the indicated concentrations for 4 hours. Cells were then washed
to remove drugs and replated in fresh R10 medium. Cell viability was then measured by 7-AAD staining and flow cytometry. For A and B, shown are
graphs of mean values taken from triplicate wells 6 SEM following subtraction of background (% 7-AAD+ in no drug controls). P values were
calculated by two-way ANOVA with Dunnett’s multiple comparison test (comparing to the no drug control) * p,0.05, ** p,0.01, *** p,0.001, ****
p,0.0001. C. In parallel to the viability assays shown in A and B, ACH2 cells were treated with HDACis for 4 hours, then washed and replated in fresh
medium. Shown are mean 6 SEM values for % HIV-Gag
+ cells as measured in triplicate by intracellular staining and flow cytometry.
doi:10.1371/journal.ppat.1004287.g002
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cells relative to untreated cultures. Treatment with SAHA was
associated with reduced elimination of infected cells at clone:target
ratios of 1:100 and 1:35 (mean 6 SD of proportion killed, no
treatment - 41.461.9 vs SAHA - 12.9614.4 at 1:100, and no
treatment – 63.664.7 vs SAHA 55.0611.0), but this was not
statistically significant after correction for multiple testing in this
experiment (p=0.25).
In order to isolate the effects of HDACis on CTL from potential
effects on target cells, we performed variations of the above
experiment where we pre-treated CTL with drugs at the above
concentrations for 4 hours and then washed to remove the drugs
prior to co-culturing with targets. Using an HIV-Gag-SLYNT-
VATL-specific CTL clone we tested two different ranges of
clone:target ratios (Figs. 6D (high range), 6E (low range)). In both
of these experiments we observed significantly impaired elimina-
tion of HIV-infected target cells by CTL that had been pre-treated
with SAHA, panobinostat, or romidepsin, with the most
pronounced effect at low effector to target ratios. To control for
non antigen-specific elimination of infected cells, we co-cultured
infected target cells with a CMV-pp65-specific CTL clone in
parallel to the HIV-Gag-specific CTL clone over the range of
effector:target ratios tested. We observed a lack of elimination of
infected target cells with this CMV-pp65-specific clone (data-
points are along the x-axis, Fig. 4E).
To further corroborate our results, we performed an additional
experiment with an HLA-A02-restricted HIV-specific CTL
targeting a different Gag epitope (FLGKIWPSHK). We again
observed significant impairment of infected-cell elimination by
CTL that had been pre-treated with romidepsin and SAHA
(Fig. 6F). The effect of panobinostat was not significant in this
assay, though a lesser proportion of infected targets were killed at
each of the clone:target ratios. Thus, even transient exposures to
pharmacologically relevant doses of HDACis impair the abilities of
CD8
+ T cells to eliminate HIV-infected target cells. As with other
measures of T-cell function reported above, the impairment of
Figure 3. HDAC inhibitors impair IFN-c production from PMA/ionomycin stimulated CD4
+ and CD8
+ T-cells. A, B. PBMC from subject
OM292 were exposed to HDACis for 4 hours. Cells were then washed and cultured in fresh medium with PMA/ionomycin for an additional 5 hours in
the presence of brefeldin A. A. IFN-c production in CD4
+ and CD8
+ T-cells was measured by intracellular cytokine staining flow cytometry. Shown are
mean 6 SEM values. P values were calculated by two-way ANOVA with Dunnett’s multiple comparison test (comparing to the no drug control) * p,
0.05, ** p,0.01, *** p,0.001, **** p,0.0001. B. Viability in CD4
+ and CD8
+ T-cells was measured by Annexin-V and 7-AAD staining flow cytometry.
Shown are mean 6 SEM values.
doi:10.1371/journal.ppat.1004287.g003
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treatment with romidepsin at the doses tested.
In an in vivo setting, one could envision a scenario where
exposure to HDACis induces expression of latent HIV, but then
clearance of the drug occurs, potentially allowing CTL to recover
functionality and eliminate these unmasked target cells. To model
this, we performed an additional series of viral elimination assays
where we pre-treated CTL with HDACis for 5 hours, then washed
to remove these drugs, and cultured CTL in fresh medium for 4 or
14 hours prior to a 10 hour co-culture with infected target cells
(Fig. 7A). At the high clone:target ratio of 1:10 used in this assay
we observed relatively modest impairment of viral elimination in
the 4 hour wash-out experiment by romidepsin and panobinostat
(mean 6 SD % infected targets killed, 73.061.3% - no treatment
versus 53.563.0%–50 ng/ml romidepsin, p=0.0013;
60.266.1%–50 ng/ml panobinostat, p=0.016). We did not
observe significant impairment of viral elimination by SAHA in
this experiment; 55.463.1 – 1,000 ng/ml SAHA, p=0.07)
(Fig. 7B). In the 14 hour wash-out experiment we observed
greater impairment of target cell killing in the romidepsin and
Figure 4. HDAC inhibitors impair IFN-c production from antigen-stimulated CD8
+ T-cells. A, B. PBMC or CTL clones from chronically HIV-
infected ARV-treated subjects (OM265 and OM292) were cultured for 2 hours with the indicated drugs and then plated for IFN-c ELISPOT assays with
12 hour peptide stimulation periods. A. Treated CTL clones were stimulated with overlapping 15mer peptides spanning the CMV-pp65 protein (left
panel) or the MHC-I-A24 restricted HIV-Nef peptide ‘RW8’ (right panel). Each treatment condition was tested in duplicate. Shown are mean SFC/10
4
CTL clone cells for each condition with error bars representing SEM. B. Experiments analogous to those depicted in A were performed for 8 different
optimal HIV CD8
+ T-cell epitopes (5 for OM292 and 1 for OM265). Shown are summary data for all 8 responses depicting the mean SFC/10
6 PBMC (of
triplicate wells) under different treatment conditions. For SAHA, panobinostat, and romidepsin conditions statistical significance for each drug was
evaluated using two-way ANOVA tests, and p values were calculated using Dunnett’s multiple comparison test to account for the use of three
different drug concentrations. For IL-15SA p values were calculated using the Wilcoxon matched pair test. C. PBMC from subjects OM265 and OM292
were treated with SAHA or romidepsin at the indicated concentrations for 2 hours and then either: stimulated with peptides for 6 a hour ELISPOT
assay, or washed, cultured for 24 hours in the absence of drugs, and stimulated with peptides for a 12 hours ELISPOT assay. P values were calculated
by two-way ANOVA with Dunnett’s multiple comparison test (comparing to the no drug control) * p,0.05, ** p,0.01, *** p,0.001, **** p,0.0001.
doi:10.1371/journal.ppat.1004287.g004
HDACis Impair CTL Killing
PLOS Pathogens | www.plospathogens.org 8 August 2014 | Volume 10 | Issue 8 | e1004287HDACis Impair CTL Killing
PLOS Pathogens | www.plospathogens.org 9 August 2014 | Volume 10 | Issue 8 | e1004287panobinostat treated samples, as compared to the 4 hour wash-out
(mean 6 SD % infected targets killed, 64.860.4% no treatment
versus 060%–50 ng/ml romidepsin, 27.262.3% 50 ng/ml pa-
nobinostat). In contrast, we observed a lack of inhibition in
SAHA-treated 14 hour wash-out samples (62.860.3% 1,000 ng/
ml SAHA). The differences in elimination of infected cells between
the 4 hour and 14 hour wash-out experiments were significant
across the dose ranges tested, by two-way ANOVA, for romidepsin
(p=0.0187) and for panobinostat (p=0.0231). These differences
for SAHA were not significant (p=0.065), and, in contrast to
romidepsin and panobinostat, the trend for SAHA was towards
improved elimination of infected cells following the rest period.
Based on our data from Figs. 1 and 2, we postulated that the
exacerbation, rather than recovery, of CTL impairment over the
14 hour wash-out period was due to the progressive loss of viability
of cells following romidepsin or panobinostat treatment, even
following HDACi removal. In order to test this, we had
maintained CTL in culture in parallel to these elimination assays.
Contemporaneously with the termination of elimination assays, we
assessed the viability of CTL in these cultures by assessing the
frequencies of apoptotic (Annexin-V
+) and dead (7-AAD
+) cells by
flow cytometry (Fig. 7C). We observed the dose dependent
induction of apoptosis (Annexin-V
+) in CTL that had been
exposed to romidepsin and, to a lesser extent, panobinostat. Thus,
in-line with our previous results, rather than allowing for recovery
of CTL function, a wash-out period exacerbated the impairment
of infected-cell elimination by romidepsin and panobinostat. In
contrast, exposure to SAHA at these doses was not associated with
the induction of apoptosis.
Visualizing the Effects of HDAC Inhibitors on CTL Killing
in 3D Collagen Matrices by Time-Lapse Microscopy
To effectively eliminate HIV-infected target cells in vivo, CTL
need to migrate through the extracellular matrix to catch and kill
moving targets. We visualized the effects of pharmacologically
relevant doses of romidepsin and SAHA on the killing activity of
an HIV-Gag-SLYNTVATL-specific CTL in a 3D collagen matrix
designed to approximate this in vivo environment as has been
previously described [45]. CTL were membrane-labeled with
Alexa-Fluor555-conjugated cholera toxin B and pre-treated with
the indicated drugs for 24 hours, or maintained as no-treatment
controls. These effectors were then mixed with peptide-pulsed
BLCL expressing the restricting class I allele in a collagen matrix
and visualized by time-lapse brightfield and fluorescence micros-
copy. CTL are identified in these images by fluorescence from the
Alexa-Fluor555 label (red in images), and dead cells acquire
fluorescence by permitting a sytox green dye in the medium to
pass through their disrupted membranes and bind to genomic
DNA (green in images). Untreated CTLs migrated through the
collagen matrix and efficiently killed target cells. Images from a
representative field of view are shown in the top panels of Fig. 8A
and the corresponding movie is given in Supporting Movie S1.
The yellow arrow follows a migrating CTL that engages and kills a
target cell marked with a white arrow. In total, three CTL:target
cell engagements and kills are observed in this field of view within
1 hour 40 minutes. Killed target cells appear green due to the
ability of sytox dye to pass through their compromised membranes
and bind to nuclear DNA. For the CTL treated with romidepsin
or SAHA we observed less efficient killing of target cells. The
images in the middle panel of Fig. 8A correspond to Supporting
Movie S2 and follow a SAHA-treated CTL (yellow arrow) that
migrates and engages with a target cell (white arrow). The CTL
fails to kill this target and instead is dragged through the collagen
until the target cell pulls away and escapes out of frame. In
Supporting Movie S2 one can see that this CTL subsequently
engages with a second target cell that it also fails to kill. Two other
CTL are observed in the two right panels and, in contrast to the
no treatment condition, neither of these is associated with a killed
target cell. The lower panel corresponds to Supporting Movie
S3 and shows a similar event observed in the romidepsin condition
where a CTL (yellow arrow) engages with a target cell (white
arrow) but fails to kill it. The target cell pulls the CTL along and
then escapes Fig. 8A. In-line with previous experiments, we did
also observe an increased frequency of dead/apoptotic CTL (non-
motile, small condensed cytoplasm) in association with romidepsin
treatment (Fig. 8B, middle panel, pink arrow). The total numbers
of killed target cells following 20 minutes of imaging were counted
in four fields of view (FOV) each for the three treatment
conditions. Overall, we observed significantly fewer killing events
in the wells containing CTL that had been treated with
romidepsin (p=0.011), but no significant effect of SAHA
treatment (p=0.181) Fig. 8B. Thus, treatment with romidepsin
impairs the ability of CTL to kill peptide-pulsed target cells in a
3D model of the extracellular environment. The two modes of
romidepsin-induced impairment supported by the data presented
in previous figures – functional impairment of viable cells, and
delayed onset apoptosis – were directly visualized in this
experiment with both an apoptotic and a viable but ineffective
CTL present in the romidepsin FOV presented in Fig. 8B.
Discussion
In this study we explored the potential for HDACi latency-
reversing drugs to impact upon multiple functions of virus-specific
CTL. We observed that romidepsin, panobinostat, and SAHA all
rapidly suppressed IFN-c production from virus-specific CD8
+ T-
cells. The proliferation of both CD8
+ and CD4
+ T-cells in
response to either CMV-pp65 or HIV-Gag peptide pools was
abrogated by treatment with romidepsin, while the effects of
SAHA and panobinostat on proliferation were only significant for
the CD8
+ T-cell response to CMV-pp65. Critically, each of these
HDACis also impaired the ability of HIV-specific CTL to
eliminate infected CD4
+ and peptide pulsed BLCL as measured
in liquid culture and collagen matrices respectively.
The overall data support the idea that there are mechanisms
both involving and independent of losses in T-cell viability at play,
and that these make differential contributions depending on the
Figure 5. HDAC inhibitors impair proliferation of virus-specific T-cells. PBMC from 11 chronically HIV-infected subjects on suppressive ARV
therapy were labeled with CFSE and treated with the indicated drugs for 4 hours. HIV-Gag or CMV-pp65 peptide pools were then added to final
concentrations of 1 mg/ml/peptide. 48 hours later, cells were washed thoroughly, re-suspended in medium with 20 U/ml IL-2, and cultured for an
additional 5 days. Cells were then stained with a viability dye and antibodies to CD3, CD8, and analyzed by flow cytometry. A. Shown are
representative flow cytometry data of a CMV-pp65 response gated on viable, CD3
+CD8
+ lymphocytes depicting CFSE (diminution indicates
proliferation) – x-axis by CD8 – y-axis. B–E. Summary data depicting frequencies of CFSEdim cells within viable, CD3
+CD8
+ or CD3
+CD8
2 (CD4
2 T-cell)
lymphocyte populations. F. Shown are data analogous to B–E, but from a separate experiment where peptides were added back with fresh medium
following HDACi wash-out at 48 hours. P values were calculated by the Wilcoxon matched-pairs signed rank test.
doi:10.1371/journal.ppat.1004287.g005
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+ cells. CD4
+ T-cells were enriched from HIV-uninfected A02
+
donors and either infected with HIV JR-CSF or maintained as mock infected controls. 24 hours post-infection, these target cells were co-cultured with
an HIV-Gag- or CMV-pp65-specific CTL clones at the indicated effector (clone):target (CD4
+ cell) ratios for 16 hours. Cells were then stained with
fluorochrome conjugated antibodies to CD8, CD4, and HIV-Gag (intracellular staining) and analyzed by flow cytometry. A. Shown is the gating
strategy utilized for killing assays, with the placement of Gag
+ and Gag
+CD4
dim gates determined based on a mock-infected control (right panel). B.
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times, and the type of effector cell (ex vivo T-cells, or in vitro
expanded CTL clone). The data presented in Figs. 1 and 2
clearly demonstrate that romidepsin and, to a lesser extent,
panobinostat are disproportionately toxic to activated T-cells as
compared to their resting counterparts. However, data presented
in Fig. 3 demonstrate that all 3 HDACis suppress IFN-c
production from viable T-cells. In the case of romidepsin, our
data support the idea that these two modes of suppression are
linked, with early suppression of functionality followed by later
onset of apoptosis. However, in the case of SAHA, functional
suppression appears to occur in the absence of any impact on cell
viability. Treatment with panobinostat appears to be intermediate
between these two situations, depending also upon the exposure
concentration.
We propose that the net effects of HDACi treatment on HIV-
specific T-cells in the majority of our functional assays involved
contributions from both of these modes of suppression, particularly
in the case of romidepsin. For example, the impaired abilities of
romidepsin-treated CTL to eliminate HIV-infected target cells
over 16 hour co-cultures likely resulted both from rapid suppres-
sion of CTL function (CTL are capable of killing target cells within
2–10 minutes [46–48]) as well as apoptosis at later time-points
post-exposure. This is supported by the observed exacerbation of
this impairment following a 14 hour romidepsin wash-out period
(Fig. 7). This is also directly visualized in Fig. 8A, and
Supporting Movie S3. Here, following romidepsin treatment,
apoptotic CTL are visible, but a CTL also remains viable
(excludes sytox dye) throughout the 5:34 (h:mm) imaging, while
failing to kill a target cell that it engages from 1:03 to 2:26. These
two modes of HDACi-induced CTL impairment – inhibition of
function in viable T-cells and reduction in T-cell viability (with the
former leading to the latter in some cases) – have the potential to
have different impacts in a therapeutic setting. It may be possible
to mitigate the impact of transient CTL impairment on flush-and-
kill eradication strategies by designing dosing schedules that target
a temporal therapeutic window, whereby either HIV antigen
expression occurs before CTL are substantially impaired, or
persists while CTL are given time to functionally recover. A better
understanding of the kinetics and durability of HIV antigen
presentation from reactivated latently-infected cells is required to
evaluate the plausibility of this approach. On the other hand,
losses in viability of activated CTL, as we observed in vitro with
romidepsin and, to a lesser extent, panobinostat, could result in an
irreversible impairment of virus-specific cellular immune respons-
es, particularly if HIV-specific T-cell responses are primed first, for
example by therapeutic vaccination. Thus, our data suggest that
the potential for a given HDACi to impair CTL function both in
the first few hours of treatment when viability is intact, and over
longer time-lines by the gradual induction of cell death should be
considered in designing flush-and-kill approaches.
Our findings are limited to ex vivo and in vitro experiments, and
the extent to which HDACis impact CTL function in HIV-
infected patients is presently unknown. On one hand, the
clearance of drugs in vivo may serve to mitigate some of the
effects of HDACis on HIV-specific CTL, although we attempted
to account for this by washing out drug in most assays. On the
other hand, our in vitro experiments incorporated only single
doses of HDACis whereas the SAHA and panobinostat clinical
trials have incorporated repeated dosing. This could potentially
exacerbate any effects, particularly if these drugs cause lasting
changes to the T-cell functional profile, or compromise the
survival of T-cells. In the CLEAR trial, for example, patients
received panobinostat on days 1, 3, and 5 every other week for 8
weeks. An additional challenge to predicting whether a therapeutic
window between latency reversal and CTL inhibition exists is that
infected cell elimination assays, which utilized highly functional
CTL clones, at relatively high effector:target ratios in most
experiments, and activated target cells expressing high levels of
HIV-Gag, can be interpreted as an idealized environment for
CTL killing of target cells. Thus, it is reasonable to speculate that
even a subtle difference in killing efficiency observed in our in vitro
assays may manifest as a critical difference in vivo where CTL are
likely to be exhausted or otherwise functionally impaired, and
where CTL encounters with reactivated target cells are rare.
Following from this, while we did not observe significant
impairment of infected cell killing at 1 nM or 5 nM of
panobinostat, we cannot rule out that more subtle impairments
in function may lead to reductions in abilities of CTL to eliminate
exposed natural reservoir cells in vivo. Based on the magnitudes of
the effects observed in vitro, along with consideration of the
pharmacokinetic and pharmacodynamic properties of these drugs,
at the dosing regimens being taken forwards into HIV clinical
trials we propose that HDACis are differentially likely to impact
upon relevant T-cell functions in vivo, with the following
hierarchy: romidepsin.panobinostat.SAHA. Ultimately, howev-
er, we hope that the primary outcome of our study will be to
motivate the incorporation of assays measuring ex vivo T-cell
function into ongoing and planned HDACi clinical trials, and that
immunosuppression will be considered as a potential factor
limiting the effectiveness of any observed outcomes.
We must also highlight, in a more general sense, the potential
risk of treating HIV-infected subjects, whose immune systems do
not fully recover even with ART, with HDACis. In addition to the
ex vivo and in vitro data presented in the current study, a number
of studies have observed in vivo immunosuppressive activities of
HDACis, including romidepsin and SAHA [16–20]. While
opportunistic infections have not been reported in HIV-infected
subjects receiving SAHA and panobinostat, this is a greater
concern for romidepsin. We observed greater impairment of CTL
function, and toxicity with romidepsin treatment as compared to
panobinostat and SAHA at the doses tested. Lymphopenia is also
known to be a common side-effect of romidepsin treatment, and
serious and sometimes fatal infections, including pneumonia and
sepsis, have been reported in clinical trials in oncology settings
[49]. Notably though, these side-effects were observed at higher
doses than those planned for HIV eradication trials. The
incorporation of immunological end-points as important safety
Data from a representative experiment with indicated effector:target ratios of an HIV-Gag-SLYNTVATL-specific T-cell clone. Panels C–F utilize total
Gag
+ cells and calculate a % Infected Cells Killed as (%Gag
+ No Effectors - %Gag
+ at Given E:T ratio)/%Gag
+ No Effectors*100, ex. in panel B %Infected
Cells Killed at 1:36 ratio=(22.126.7)/22.1*100=69.7%. C–F. Shown are the results from 4 independent experiments. In C CTL were treated with
romidepsin or panobinostat at 50 nM or with SAHA at 500 nM for 2 hours, and then co-cultured with target cells without a washing step. In D–F CTL
were treated with romidepsin or panobinostat at 25 nM or with SAHA at 500 nM for 6 hours, then washed thoroughly before initiating a 16 hour co-
culture with target cells. D and E both utilize an HIV-Gag-SLYNTVATL-specific CTL clone at high and low E:T ratios respectively. E utilizes an HIV-Gag-
FLGKIWPSHK-specific CTL clone. C–F. Shown are means 6 SEM of data from triplicate wells. P values were calculated by two-way ANOVA with
Tukey’s multiple comparison test.
doi:10.1371/journal.ppat.1004287.g006
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specific CTL clone was treated with panobinostat, romidepsin, or SAHA at the indicated doses for 5 hours, or maintained as an untreated control.
Cells were then washed two times, resuspended in R10–50, and cultured for 4 or 14 hours. These CTL were then co-cultured with autologous HIV-
infected CD4
+ T-cells at a clone:target ratio of 1:10 for 8 hours, and levels of infection were measured as described above (see Fig. 4 legend). A.
Shown are flow cytometry plots gated on the viable (FSC/SSC) CD8
2 population, and depicting HIV-Gag staining (x-axis) by CD4 staining (y-axis). For
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infected subjects would help to address concerns regarding a
potential impact on the immune system in general. The possibility
that romidepsin or other HDACis could impair HIV-specific T-
cell responses in vivo should also be ruled out before any therapy
interruptions are contemplated as part of eradication trials, given
the importance of CTL in containing any rebound viremia.
The HIV-specific cellular immune response, in addition to
playing a vital role in the ongoing health of HIV-infected
individuals, stands to make a powerful contribution to HIV
eradication strategies. Thus we would make a case that a critical
stage in evaluating potential latency reversing drugs to be used in
CTL-based flush-and-kill strategies should be to test the effects of
these drugs on the functions of HIV-specific T-cells. This
information can both be used to help prioritize classes of
candidates, and to select optimal drug candidates from within a
class. We would also suggest that this should be extended to flush-
and-kill strategies focused on other immune effectors. Notably,
romidepsin has also been reported to both suppress the cytotoxic
activity and to drive apoptosis of NK cells, which are another
potential key immune effector in flush and kill strategies [24].
Information regarding how a drug influences CTL and other
immune effectors should be generated along with other param-
eters such as EC50 and toxicity in order to prioritize candidates.
Through screening efforts, or rational design based on an
improved understanding of the mechanisms by which HDACis
exert their immunosuppressive effects, it may also be possible to
identify HDACis that retain the ability to induce the expression of
latent HIV without impairing the ability of CTL or other immune
effectors to eradicate these unmasked targets.
Materials and Methods
Ethics Statement
HIV-infected individuals were recruited from the Maple Leaf
Medical Clinic in Toronto, Canada through a protocol approved
by the University of Toronto Institutional Review Board and from
the Boston area (United States) under a protocol approved by the
Institution Review Board at the Massachusetts General Hospital.
Secondary use of the samples from Toronto was approved through
the Massachusetts General Hospital Institutional Review Board.
All subjects were adults, and gave written informed consent.
Clinical data for study subjects are given in Table 1.
Latency Reversing Drugs
Romidepsin was purchased from Selleckchem. An 18.5 mM
stock was prepared in 100% DMSO (hybrimax, Sigma). This was
diluted 3,7006in PBS to give a working stock of 5 mM in 0.03%
DMSO. SAHA was purchased from Sigma and dissolved to
10 mM in 100% DMSO. This was diluted to a working stock of
1 mM in PBS (10% DMSO in working stock). Panobinostat was
obtained from Selleckchem as a 10 mM stock in DMSO. This was
diluted 5006in in PBS to give a working stock of 20 mM in 0.2%
DMSO. ALT-803 is an IL-15 superagonist (IL-15SA) produced by
Altor Bioscience Corporation [50,51]. IL-15 has previously been
shown to increase the magnitude of HIV-specific T-cell responses
as detected by IFN-c ELISPOTS through a mechanism involving
STAT1, STAT3, STAT4, and STAT5 [52,53], and thus allowed
for a control for cell responsiveness to soluble factors that impact
cellular functions. ALT-803 was obtained from Altor Bioscience
Corporation at 1.38 mg/ml in PBS, and was used at a working
stock of 50 mg/ml. The concentrations of HDACis used in
experiments were selected to be pharmacologically relevant to
current clinical trials. The mean clinical Cmax of panobinostat at
the 20 mg p.o. dosing regimen of the ongoing CLEAR trial is
40 nM [54], the steady-state plasma concentration is 15 to 22 nM
(Novartis Investigator’s brochure), and the EC50 values for in vitro
HIV activation in cell line models of latency has been reported to
range from 10–16 nM [11,55]. The mean Cmax of SAHA given at
400 mg p.o. as in the two latency reactivation trials that have been
conducted is 1 mM [56], and the reported EC50 values for in vitro
HIV activation in cell line and primary cell models of latency
range from 885–3,950 nM [11,55,57]. The mean clinical Cmax
values for of romidepsin in the intermediate and high dosing arms
of the upcoming dose escalation study in HIV-infected subjects
(ClinicalTrials.gov Identifier: NCT01933594) are: 2 mg/m
2,C max
69.5632.6 nM, and (5 mg/m
2, 178.1632.6 nM), and the report-
ed EC50 values for in vitro HIV activation in a cell line and
primary cell models of HIV range from 3–4.5 nM [55,57].
T-Cell Viability Assay
PBMC were obtained from HIV-negative buffy coats, or from
cryopreserved leukophersis samples from HIV-infected subjects (as
indicated). CTL clones were taken from long-term in vitro cultures
(restimulated bi-weekly). Cells were plated at 200,000 cells/well
(PBMC) or 50,000 cells/well (CTL clones) in 200 ul of RPMI-
1640+10% FBS (R10) medium (PBMC) or R10+50 U/ml IL-2
(CTL clones) in 96-well round-bottom plates. Where indicated,
cells were stimulated with 1 mg/ml each of anti-CD3 (OKT3
clone) and anti-CD28 (CD28.2 clone), both from eBioscience, for
48 hours prior to HDACi addition. HDACis were added at the
indicated concentrations with all conditions tested in triplicate.
Cells were cultured at 37uC, 5% CO2 for 4 the indicated periods
of time. Where indicated, HDACis were washed out with
26250 ml medium and cells were replated in fresh medium. At
the time of harvest, cells were stained with Annexin-V-Fitc, 7-
AAD, anti-CD4 pacific blue (BioLegend), and anti-CD8 alexa-
fluor 700 (BioLegend) using the FITC Annexin V Apoptosis
Detection Kit with 7-AAD (BioLegend), washed, fixed in 4%
paraformaldehyde and then analyzed immediately on an LSR-II
flow cytometer.
PMA/Ionomycin Intracellular Cytokine Staining Assays
PBMC were plated at 100,000 cells/well in 96-well round
bottom plates in R10 medium and HDACis were added at the
indicated concentrations. Following 4 hours of exposure, cells
were washed with 26250 ml medium and then cultured with
200 ml fresh R10 medium+1/500 dilution of the 5006 PMA/
ionomycin cell stimulation cocktail (eBioscience) in the presence of
1 mg/ml Brefeldin A (BD). Following a 5 hour stimulation period,
cells were split and stained with either: i) anti-CD4 pacific blue
the plots show, CTL that had been treated with romidepsin were given a 14 hour wash-out period prior to co-culture with infected cells. B. Shown are
summary flow cytometry for 4 hour wash-outs (left panels) and 14 hour wash-outs (right panels). Each condition was tested in duplicate. Error bars
represent SEM. C. Portions of the CTL used in the above elimination assays were maintained in culture. At the conclusions of the 14 hour wash-out
elimination assay, 29 hours in total since addition of drugs, the frequencies of dead (7-AAD
+) and apoptotic (Annexin-V
+) CTL were measured by flow
cytometry. Shown are % Annexin-V
+ following treatment with the indicated doses of drugs. Error bars represent SEM. P values were calculated by
two-way ANOVA with Dunnett’s multiple comparison test (comparing to the no drug control) * p,0.05, ** p,0.01, *** p,0.001, **** p,0.0001.
doi:10.1371/journal.ppat.1004287.g007
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bilized (cytofix/cytoperm, cytoperm/wash, BD) and stained
intracellularly with anti-IFN-c FITC (to measure IFN-c produc-
tion) ii) Annexin-V-Fitc, 7-AAD, anti-CD4 pacific blue (BioLe-
gend), and anti-CD8 alexa-fluor 700 (BioLegend) using the FITC
Annexin V Apoptosis Detection Kit with 7-AAD (BioLegend) (to
measure viability). Cells were fixed % paraformaldehyde and then
analyzed immediately on an LSR-II flow cytometer.
Generation of T-Cell Clones
PBMCs were stimulated with optimal CD8 T-cell epitopes for
6-hours, enriched for antigen-specific cells using the IFN-c
secretion Detection and Enrichment Kit (Miltenyi), and cloned
at limiting dilution on irradiated feeder cells as has been previously
described [58]. Clones were selected from 96-well plates at
dilutions where no more than 1 in 5 wells displayed growth and
screened for specificity by IFN-c ELISPOT. Specific clones were
expanded on irradiated feeder cells.
IFN-c ELISPOT
ELISPOT assays were performed as previously described [59].
CD8
+ T-cell clones were plated at 10,000 cells/well with 50,000
autologous EBV-transformed B cell lymphoblastoid cell lines
(BLCL) as target cells. Peripheral blood mononuclear cells
(PBMC) were plated at 100,000 cells/well. Peptides representing
optimal HIV CD8
+ T-cell epitopes were used at final concentra-
tions of 1 mg/ml/peptide, while the pool of overlapping CMV-
pp65 15mer peptides (JPT peptide technologies) was used at 1 mg/
ml/peptide. Cells were incubated for 16 hours with peptide in
ELISPOT plates before beginning development. The number of
specific spot-forming cells (SFC) was calculated by subtracting the
background number of spots in the negative control (DMSO only)
control wells from the number of spots in the experimental well.
For assays performed on CTL clones values are reported as SFC
per thousand CTL clone cells. For assays performed on PBMC
values are reported as SFC per million PBMC.
Proliferation Assays
PBMC from 12 ARV-treated HIV-infected subjects were
thawed and labeled with 0.5 mM CFSE in PBS. Cells were plated
at 100,000 cells/well in 96-well round bottom plates in R10.
Triplicate wells were prepared for each experimental antigen/
drug combination, and outside wells of the plate were filled with
PBS. HDACis or ALT-803 were added in 50 ml of R10 to final
concentrations of: ALT-803 72 ng/ml, romidepsin 25 nM,
panobinostat 25 nM, SAHA 500 nM. These concentrations were
selected to fall below the Cmax concentrations in ongoing and
planned clinical trials (see results). No treatment controls were
prepared in parallel with 50 ml of R10. Cells were incubated at
37uC, 5% CO2 for 4 hours. Pools of overlapping 15mer peptides
spanning CMV-pp65 (Positive Control Pool Pepmix
HCMV(pp65), JPT Peptide Technologies) and 18mer peptides
overlapping by 10 amino acids spanning HIV-Gag were obtained
from the MGH peptide core facility and added to final
concentrations of 1 mg/ml/peptide. After 48 hours of further
incubation, cells were washed 26 with 200 ml of R10 and
resuspended in 200 ml of R10 supplemented with 20 U/ml IL-2
(NIH AIDS reagent program). Where indicated, the Gag peptide
pool was re-added along with this fresh medium at a concentration
of 1 mg/ml/peptide. Following an additional 5 days of culture (7
days total) cells were stained with anti-CD4 pacific blue, anti-CD8
alexafluor700, and anti-CD3 PE-CY7 (all antibodies from
Figure 8. Time-lapse microscopy of CTL killing of peptide pulsed BLCL target cells in 3D collagen matrices. An HIV-Gag-SLYNTVATL-
specific CTL clone was labeled with Alexa-Fluor555 conjugated cholera toxin subunit B either cultured with 500 nM SAHA or 25 nM romidepsin for
20 hours, or maintained as an untreated control. These effector cells were combined with SLYNTVATL peptide pulsed target cells, matched on the
restricting allele, in a collagen matrix medium containing sytox green viability dye. These mixtures were then plated in three separate wells of an 8-
well cover slip and imaged by time-lapse brightfield and fluorescent microscopy. A. Shown are representative fields of view from the no treatment
(upper panel), 500 nM SAHA (middle panel), and 25 nM romidepsin (lower panel) conditions advancing in time from left to right. Time stamps are
given in hh:mm format. Clones described in the results are indicated with yellow arrows and killed target cells are indicated with white arrows in the
upper right panel. B. The number of killed (sytox green positive) BLCL at T=20 minutes were counted in each of the four fields of view acquired for
each condition. Each field of view is plotted as a single point on the graph along with means and SD. P values were calculated by the Kruskal-Wallis
test. The reported values are corrected for multiple testing using Dunn’s multiple comparison test.
doi:10.1371/journal.ppat.1004287.g008
Table 1. Clinical characteristics of study subjects.
ID Viral Load CD4 count ART Regimen Treatment Duration
653116 20 624 Emtricitabine, Tenofovir, efavirenz 81 months
514023 20 1258 Emtricitabine, Tenofovir, atazanavir, ritonavir 92 months
128450 40 635 Emtricitabine, Tenofovir, Raltegravir 23 months
198605 50 1234 Combivir, Tenofavir 66 months
296260 20 671 Emtricitabine, Tenofovir, efavirenz 62 months
379080 48 643 Atripla 53 months
394747 48 711 Atripla 39 months
403998 20 738 Atripla 48 months
409231 50 795 Tenofavir, Kaletra, Abacavir 19 months
498553 48 1128 Ritonavir, Atazanavir, Truvada 20 months
557014 20 1426 Truvada, Raltegravir 35 months
doi:10.1371/journal.ppat.1004287.t001
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instrument. Data were analyzed using Flowjo software (Treestar).
Production of HIV
The HIV molecular clone JR-CSF was obtained from the NIH
AIDS Reagent Program (www.aidsreagent.org). Viral stocks were
produced by transfection of 293T cells using Fugene HD
(Promega) following the manufacturer’s instructions. Superna-
tants were harvested 48 hours post-transfection, centrifuged at
1,0006g for 5 minutes to pellet cell debris, and filtered through a
400 mM membrane (Steriflip, Millipore). Viral titers were
determined by titration on primary cells by the Ragon Institute
Virology Core.
ACH2 Latency Reversal Assays
The chronically HIV-infected ACH2 cell line was maintained in
R10 medium. Cells were plated at 100,000 cells/well in 96-well
round-bottom plates. Latency reversal drugs were added at the
indicated concentrations and incubated for 4 hours. Cells were
then washed two times to remove drugs, replated in fresh R10
medium, and cultured for an additional 20 hours. Cells were fixed
and permeabilized using cytofix/cytoperm and perm/wash
reagents (BD) and then stained intracellularly with anti-HIV-
Gag KC57-RD1 (Beckman Coulter) diluted 1/100 in perm/wash
buffer. After washing to remove unbound antibodies, cells were
analyzed on a FACSCalibur instrument (BD).
HIV Elimination Assays
HIV-Gag SLYNTVATL and FLGKIWPSHK specific CD8
+
T-cell clones were obtained from two different HIV-infected elite
controller subjects and maintained as previously described
[58,60]. The specificities and cytotoxic potential of these clones
were confirmed two days prior to performing each elimination
assay experiment by measuring degranulation in response to
cognate peptide stimulation by a CD107a-staining flow cytometry
method [61]. On this same day, HLA-A02
+ PBMC from HIV-
uninfected subjects were thawed and enriched for CD4
+ T-cells
by negative selection (Easysep, Stemcell Technologies). These
CD4
+ T-cells were stimulated with 1 mg/ml each anti-CD3
OKT3 and anti-CD28.2 antibodies (eBioscience) in R10 supple-
mented with 50 U/ml IL-2 (NIH AIDS Reagent Program) for
48 hours. These activated target cells were infected with HIV JR-
CSF using a previously described magnetofection method [62].
Infection levels were monitored by flow cytometry staining for
CD4 (BioLegend) and intracellularly for HIV-Gag (KC57 clone,
Beckman Coulter). Targets were determined to be ready for use
in the elimination assay when they were 20% Gag
+ by flow
cytometry. At this time-point, CTL clones were split into equal
aliquots and cultured in R10+50 U/ml IL-2 supplemented with
HDACis and ALT-803 as indicated. Following 4 hours of
incubation in 5% CO2 at 37uC, CTL were washed with 36
with 1 ml R10. Target CD4
+ T-cells were plated at 50,000 cells/
well in 96-well round-bottom plates, and CTL were added at the
indicated effector:target ratios. Each condition was set up in
triplicate. Co-culture was allowed to proceed for 16 hours at
37uC, 5% CO2. Cells were then surface stained with anti-CD8-
Fitc and anti-CD4-APC (BioLegend), permeabilized (cytofix/
cytoperm, BD) and stained intracellularly with anti-HIV-Gag-PE
at 1/100 dilution (KC57 clone, Beckman Coulter). Cells were
then fixed with 4% formalin in PBS and analyzed on an LSR-II
flow cytometer instrument (BD Biosciences). Data were analyzed
using Flowjo software (Treestar).
Time-Lapse Microscopy of CTL Killing in 3D Collagen
Matrices
Following confirmation of functional activity (see above), an
HIV-Gag-specific CTL clone was labeled with 5 mg/ml cholera
toxin subunit B AlexaFluor 555 (Life Technologies) in 0.5 ml
R10+50 U/ml IL-2 for 10 minutes at 37uC. Cells were washed,
split into equal aliquots in R10+50 U/ml IL-2 and treated with
HDACi drugs at the indicated concentrations for 14 or 24 hours.
HLA-A02
+ BLCL were then pulsed with 100 ng/ml SLYNT-
VATL Gag peptide for 30 minutes, and washed. CTL and BLCL
were each resuspended to final concentrations of 2.7610
6 cells/ml
in R10+50 U/ml IL-2. 3D collagen time-lapse microscopy was
performed as previously described [45].
Statistical Analysis
Statistical analyses were performed using Prism software
(Graphpad). The statistical tests used to calculate p values are
indicated in the corresponding figure legends.
Supporting Information
Figure S1 Effects of HDACis on the viability of PBMC
CD8
+ and CD4
+ T-cells from HIV-infected subjects, and
on HIV-specific CTL clones. A. Cryopreserved PBMC from
the ARV-treated HIV-infected subjects OM292 and OM265 were
thawed and then treated with HDACi drugs at the indicated
concentrations for 6 hours. Cells were harvested at the indicated
time-points 21 hours and stained with 7-AAD (stains DNA of dead
cells), CD4, CD3, and CD8. Conditions were tested in triplicate.
Shown are summary data depicting means 6 SEM. P values were
calculated by two-way ANOVA with Dunnett’s multiple compar-
ison test (comparing to the no drug control) * p,0.05, ** p,0.01,
*** p,0.001, **** p,0.0001.
(EPS)
Movie S1 Time-lapse microscopy of untreated CTL
with peptide pulsed BLCL target cells. Shown is a time-
lapse microscopy movie corresponding to the images depicted in
the upper panel of Fig. 7A.
(MOV)
Movie S2 Time-lapse microscopy of SAHA-treated with
peptide pulsed BLCL target cells. Shown is a time-lapse
microscopy movie corresponding to the images depicted in the
middle panel of Fig. 7A.
(MOV)
Movie S3 Time-lapse microscopy of romidepsin-treat-
ed with peptide pulsed BLCL target cells. Shown is a time-
lapse microscopy movie corresponding to the images depicted in
the lower panel of Fig. 7A.
(MOV)
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